# US 2023/0399626 A1 · Generation of conditioned media from inducible pluripotent stem cell derived endothelial progenitor cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399626 A1
- Document ID: US20230399626A1
- Status: Published application
- Kind: A1
- Application number: 18/331,048
- Filed: 2023-06-07
- Published: 2023-12-14
- Earliest claimed: 2022-06-10
- Assignees: Creative Medical Technologies, Inc.
- Applicants: Creative Medical Technologies, Inc.
- Inventors: Thomas ICHIM; Amit PATEL; Courtney BARTLETT
- Web page: https://patentgrep.com/patent/US20230399626A1

## CPC

- C12N 5/069: {Vascular Endothelial cells}
- C12N 5/0692: {Stem cells; Progenitor cells; Precursor cells}
- C12N 2501/60: Transcription factors
- C12N 2506/28: from vascular endothelial cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are means, methods and compositions of matter useful for generation of conditioned media from endothelial progenitor cells (EPC). In one embodiment, EPC are extracted, dedifferentiated into inducible pluripotent stem cells (iPSC) and said iPSC are differentiated into the EPC lineage. The differentiated EPC are utilized as producers of conditioned media for therapeutic purposes. In one embodiment EPC are subjected to one or more stressors, after which conditioned media is extracted and in some cases concentrated. Said conditioned media can be utilized as a therapeutic agent or can be used in the generation of immune modulatory cells.

## Claims

### Claim 1

A method of creating an endothelial progenitor cell (EPC) conditioned media comprising the steps of: a) obtaining a cellular population; b) dedifferentiating said cellular population; c) inducing differentiation of said dedifferentiated cell into EPC; and d) culturing said EPC in a liquid media to obtain a conditioned media.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cellular population is an EPC.

### Claim 3 (depends on 2)

The method of claim 2, wherein said EPC is derived from a source selected from the group consisting of: a) peripheral blood; b) bone marrow; c) placenta; d) cord blood; e) menstrual blood; f) amniotic fluid; and g) cerebral spinal fluid.

### Claim 4 (depends on 2)

The method of claim 2, wherein said EPC express VEGF-receptor 2.

### Claim 5 (depends on 2)

The method of claim 2, wherein said EPC express interleukin-3 receptor.

### Claim 6 (depends on 1)

The method of claim 1, wherein said cellular population is monocytes.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cellular population is hematopoietic stem cells.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cellular population is a mesenchymal stem cell.

### Claim 9 (depends on 8)

The method of claim 8, wherein said naturally occurring mesenchymal stem cells are tissue derived.

### Claim 10 (depends on 8)

The method of claim 8, wherein said naturally occurring mesenchymal stem cells are derived from a bodily fluid.

### Claim 11 (depends on 10)

The method of claim 10, wherein said tissue derived mesenchymal stem cells are derived from umbilical cord tissue.

### Claim 12 (depends on 10)

The method of claim 10, wherein said tissue derived mesenchymal stem cells are isolated from tissues containing cells selected from the group consisting of: endothelial cells, epithelial cells, dermal cells, endodermal cells, mesodermal cells, stems, osteocytes, chondrocytes, natural killer cells, dendritic cells, hepatic cells, pancreatic cells, stromal cells, salivary gland mucous cells, and salivary gland serous cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein said dedifferentiation is accomplished by introduction into cells proteins capable of inducing dedifferentiation.

### Claim 14 (depends on 13)

The method of claim 13, wherein said pluripotency marker is TRA-1-60.

### Claim 15 (depends on 13)

The method of claim 13, wherein said proteins capable of inducing dedifferentiation are selected from the group consisting of: a) OCT4; b) NANOG; c) KLF-1; d) SOX-2; and e) h-RAS.

### Claim 16 (depends on 13)

The method of claim 13, wherein mRNA is introduced into said cells in order to induce expression of pluripotency inducing genes.

### Claim 17 (depends on 1)

The method of claim 1, wherein said dedifferentiated cells are capable of proliferating for more than 50 passages.

### Claim 18 (depends on 1)

The method of claim 1, wherein said redifferentiated cells are capable of proliferating for more than 50 passages and have stable karyotype.

### Claim 19 (depends on 1)

The method in claim 1, wherein said redifferentiated cells are a direct therapeutic effector.

### Claim 20 (depends on 1)

The method in claim 1, wherein said redifferentiated cells are more potent than naturally occurring EPCs based on a) VEGF production b) nitric oxide release and c) angiogenesis/capillary formation assay.
